The news: TikTok is restricting access to some peptide-related content, according to The Verge. Searches for terms including BPC-157 and retatrutide now return “no results found,” though other peptide-related searches still surface videos. It’s unclear when the restrictions began.

For context: Peptides are chains of amino acids found in FDA-approved drugs like GLP-1 medications, as well as unapproved wellness products promoted for injury recovery, weight loss, and anti-aging. This broad category likely makes content moderation challenging for platforms.

Why it matters: Unapproved wellness peptides are frequently promoted on social media, where sellers and influencers direct consumers to unauthorized suppliers and online marketplaces. Wellness and fitness influencers like biohacker Bryan Johnson and celebrity podcasters like Joe Rogan further fuel interest by discussing peptides in their wellness and longevity “stacks.” Among US clinicians whose patients have asked about peptides, 84% say those patients at least occasionally get their peptide information from online sources, including social media and podcasts, per a May Sermo survey.

On social media apps like TikTok, creators share their experiences with peptides, explain how to use them, discuss their health effects, and provide links or connections to purchase them. A recent JAMA study found that peptide-related hashtags had amassed over 230 million TikTok views as of May 2026, reflecting their increased mainstream visibility. TikTok told Endpoints News that while peptide discussions are permitted, the platform prohibits marketing high-risk products and may restrict searches for unapproved or potentially unsafe products.

Implications for social media platforms and online wellness brands: Despite peptides’ rising popularity, many promoted on social media remain unapproved, likely prompting greater platform scrutiny of related content and illegal sales.

At the same time, peptide sellers also face a powerful adversary: Big Pharma companies that invest heavily in drug approvals while unauthorized sellers market versions of some of their products. Eli Lilly, for example, is still conducting clinical trials of its GLP-1 drug retatrutide, yet peptide sellers already market purported knockoff versions as “reta.” Lilly recently took legal action against some of these sellers and called on social media platforms and online marketplaces to help curb illegal sales. While not applicable to all wellness peptides, these efforts likely mean social media promotions and influencer affiliate relationships will face more rigorous oversight as peptides enter the mainstream.